Share Price and Basic Stock Data
Last Updated: December 5, 2025, 4:49 am
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Adline Chem Lab Ltd operates in the pharmaceuticals sector, a field that has witnessed significant growth and transformation over the years. However, the company’s recent revenue trends are concerning. For the fiscal year ending March 2025, Adline reported zero sales, a stark decline from ₹6.33 lakh in March 2021 and even more alarming compared to ₹13.45 Cr in March 2014. This downward trajectory suggests a potential struggle with market positioning or operational challenges. The absence of revenue since March 2022 raises red flags about the company’s ability to generate income, leaving investors wondering about the sustainability of the business model. Moreover, the increasing public shareholding, which stood at 70.38%, indicates that retail investors are holding a significant stake, but their confidence may be tested by the company’s lack of revenue generation.
Profitability and Efficiency Metrics
Profitability metrics for Adline Chem Lab tell a discouraging story. The company has consistently reported negative net profits, with a net loss of ₹0.22 per share for the fiscal year ending March 2025. This follows a trend of losses, including a staggering ₹4.23 lakh in FY 2023. Operating profit margins (OPM) have also been negative, reflecting operational inefficiencies that have persisted over multiple quarters. The Interest Coverage Ratio (ICR) stood at a concerning -0.27x, indicating that the company struggles to cover its interest obligations, a critical measure of financial health. Furthermore, with a Return on Capital Employed (ROCE) of -74.83%, it is evident that the company’s capital utilization is severely impaired, leading to questions about whether it can turn its operational challenges around.
Balance Sheet Strength and Financial Ratios
The balance sheet of Adline Chem Lab exhibits signs of distress. The company reported reserves of -₹7.46 Cr, which is troubling when considering the long-term viability. Borrowings of ₹1.65 Cr seem manageable at first glance, but the negative reserves suggest that the company may be relying on debt to sustain operations, risking financial stability. The Price-to-Book Value (P/BV) ratio of -5.20x indicates that the market is valuing the company significantly lower than its book value, a sign of investor skepticism. While the current ratio of 4.46x appears strong, indicating that it can cover short-term liabilities, it also raises questions about the efficiency of asset utilization. The financial ratios reflect a company that is struggling to maintain a healthy balance between debts and operational performance.
Shareholding Pattern and Investor Confidence
Adline Chem Lab’s shareholding pattern provides insights into investor sentiment. Promoters hold 29.61% of the company, a stake that has remained relatively stable, suggesting some level of confidence in the business from those who know it best. However, the public, comprising 70.38% of shareholders, may be feeling the strain of ongoing losses and lack of revenue. The total number of shareholders has decreased slightly, indicating potential shareholder fatigue or disillusionment. The absence of Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) suggests a lack of institutional interest, which can be a red flag for retail investors. The reliance on public shareholders means that any continued poor performance could lead to a further decline in stock price, impacting overall investor confidence.
Outlook, Risks, and Final Insight
The outlook for Adline Chem Lab is clouded by significant risks, primarily the ongoing lack of revenue generation and consistent losses. Investors must carefully consider these factors, as the company’s operational inefficiencies and negative profitability metrics could hinder any recovery efforts. The pharmaceutical sector, while generally robust, is highly competitive, and Adline’s inability to adapt may prove detrimental. Additionally, the heavy reliance on public shareholders without institutional backing raises concerns about the stock’s stability. For investors, the path forward involves weighing the potential for recovery against the backdrop of persistent operational challenges. While there is a glimmer of hope if the company can pivot its strategy effectively, the risks associated with its current financial health cannot be overlooked.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Adline Chem Lab Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 144 Cr. | 115 | 247/84.3 | 32.0 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,214 Cr. | 384 | 479/192 | 87.3 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.4 Cr. | 45.0 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 43.7 Cr. | 29.8 | 30.5/17.0 | 104 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,299.59 Cr | 1,156.92 | 52.10 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 0.01 | 0.28 | 0.41 | 0.08 | 0.08 | 0.03 | 0.00 | 0.07 | 0.10 | 0.07 | 0.10 | 0.06 | 0.03 |
| Operating Profit | -0.01 | -0.28 | -0.41 | -0.08 | -0.08 | -0.03 | 0.00 | -0.07 | -0.10 | -0.07 | -0.10 | -0.06 | -0.03 |
| OPM % | |||||||||||||
| Other Income | 0.00 | -3.82 | 0.39 | 0.07 | 0.00 | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 | 0.25 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 | 0.00 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
| Depreciation | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.10 | -4.10 | -0.02 | -0.01 | -0.08 | -0.06 | -0.03 | -0.04 | -0.13 | -0.10 | -0.13 | 0.16 | -0.06 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -16.67% | -33.33% | 0.00% | -7.69% | -10.00% | -7.69% | -31.25% | -16.67% |
| Net Profit | -0.10 | -4.10 | -0.02 | -0.01 | -0.08 | -0.05 | -0.02 | -0.04 | -0.13 | -0.09 | -0.12 | 0.21 | -0.05 |
| EPS in Rs | -0.17 | -7.01 | -0.03 | -0.02 | -0.14 | -0.09 | -0.03 | -0.07 | -0.22 | -0.15 | -0.21 | 0.36 | -0.09 |
Last Updated: August 20, 2025, 12:25 am
Below is a detailed analysis of the quarterly data for Adline Chem Lab Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Expenses, as of Jun 2025, the value is 0.03 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.06 Cr. (Mar 2025) to 0.03 Cr., marking a decrease of 0.03 Cr..
- For Operating Profit, as of Jun 2025, the value is -0.03 Cr.. The value appears strong and on an upward trend. It has increased from -0.06 Cr. (Mar 2025) to -0.03 Cr., marking an increase of 0.03 Cr..
- For OPM %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.25 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 0.25 Cr..
- For Interest, as of Jun 2025, the value is 0.03 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.03 Cr..
- For Depreciation, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -0.06 Cr.. The value appears to be declining and may need further review. It has decreased from 0.16 Cr. (Mar 2025) to -0.06 Cr., marking a decrease of 0.22 Cr..
- For Tax %, as of Jun 2025, the value is -16.67%. The value appears to be increasing, which may not be favorable. It has increased from -31.25% (Mar 2025) to -16.67%, marking an increase of 14.58%.
- For Net Profit, as of Jun 2025, the value is -0.05 Cr.. The value appears to be declining and may need further review. It has decreased from 0.21 Cr. (Mar 2025) to -0.05 Cr., marking a decrease of 0.26 Cr..
- For EPS in Rs, as of Jun 2025, the value is -0.09. The value appears to be declining and may need further review. It has decreased from 0.36 (Mar 2025) to -0.09, marking a decrease of 0.45.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:02 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 13.45 | 15.36 | 16.94 | 17.18 | 8.10 | 5.59 | 6.59 | 6.33 | 0.74 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 12.43 | 14.42 | 16.50 | 15.97 | 7.23 | 5.01 | 9.91 | 6.56 | 1.04 | 0.80 | 0.18 | 0.30 | 0.26 |
| Operating Profit | 1.02 | 0.94 | 0.44 | 1.21 | 0.87 | 0.58 | -3.32 | -0.23 | -0.30 | -0.80 | -0.18 | -0.30 | -0.26 |
| OPM % | 7.58% | 6.12% | 2.60% | 7.04% | 10.74% | 10.38% | -50.38% | -3.63% | -40.54% | ||||
| Other Income | 0.02 | 0.08 | 0.10 | 0.08 | 0.21 | 0.25 | 0.26 | 0.00 | 1.33 | -3.35 | 0.00 | 0.25 | 0.25 |
| Interest | 0.57 | 0.48 | 0.44 | 0.32 | 0.34 | 0.07 | 0.02 | 0.03 | 0.01 | 0.00 | 0.12 | 0.16 | 0.12 |
| Depreciation | 0.46 | 0.51 | 0.09 | 0.96 | 0.73 | 0.73 | 0.42 | 1.02 | 0.35 | 0.09 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.01 | 0.03 | 0.01 | 0.01 | 0.01 | 0.03 | -3.50 | -1.28 | 0.67 | -4.24 | -0.30 | -0.21 | -0.13 |
| Tax % | 0.00% | 33.33% | 100.00% | 0.00% | 100.00% | 0.00% | 7.43% | 0.00% | -7.46% | 0.00% | -10.00% | -33.33% | |
| Net Profit | 0.01 | 0.02 | 0.01 | 0.01 | 0.00 | 0.03 | -3.76 | -1.28 | 0.72 | -4.23 | -0.27 | -0.13 | -0.05 |
| EPS in Rs | 0.02 | 0.03 | 0.02 | 0.02 | 0.00 | 0.05 | -6.43 | -2.19 | 1.23 | -7.23 | -0.46 | -0.22 | -0.09 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 100.00% | -50.00% | 0.00% | -100.00% | -12633.33% | 65.96% | 156.25% | -687.50% | 93.62% | 51.85% |
| Change in YoY Net Profit Growth (%) | 0.00% | -150.00% | 50.00% | -100.00% | -12533.33% | 12699.29% | 90.29% | -843.75% | 781.12% | -41.77% |
Adline Chem Lab Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 19% |
| TTM: | 79% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 29% |
| 3 Years: | 24% |
| 1 Year: | -13% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Last Updated: September 5, 2025, 2:06 pm
Balance Sheet
Last Updated: December 4, 2025, 2:18 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 |
| Reserves | 1.21 | 1.21 | 1.21 | 1.19 | 1.18 | 1.18 | -2.64 | -3.92 | -3.20 | -7.42 | -7.22 | -7.34 | -7.46 |
| Borrowings | 6.69 | 9.25 | 9.01 | 9.94 | 11.32 | 5.35 | 2.85 | 2.50 | 1.32 | 1.33 | 1.36 | 1.49 | 1.65 |
| Other Liabilities | 2.77 | 2.32 | 2.34 | 3.97 | 5.01 | 9.46 | 1.52 | 1.20 | 0.91 | 0.31 | 0.06 | 0.08 | 0.08 |
| Total Liabilities | 16.52 | 18.63 | 18.41 | 20.95 | 23.36 | 21.84 | 7.58 | 5.63 | 4.88 | 0.07 | 0.05 | 0.08 | 0.12 |
| Fixed Assets | 8.17 | 10.08 | 10.27 | 12.68 | 12.45 | 11.99 | 4.78 | 3.64 | 4.43 | 0.00 | 0.00 | 0.00 | 0.00 |
| CWIP | 0.20 | 0.20 | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 8.15 | 8.35 | 7.94 | 8.27 | 10.91 | 9.85 | 2.80 | 1.99 | 0.45 | 0.07 | 0.05 | 0.08 | 0.12 |
| Total Assets | 16.52 | 18.63 | 18.41 | 20.95 | 23.36 | 21.84 | 7.58 | 5.63 | 4.88 | 0.07 | 0.05 | 0.08 | 0.12 |
Below is a detailed analysis of the balance sheet data for Adline Chem Lab Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 5.85 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 5.85 Cr..
- For Reserves, as of Sep 2025, the value is -7.46 Cr.. The value appears to be worsening (becoming more negative). It has deteriorated from -7.34 Cr. (Mar 2025) to -7.46 Cr., marking a decline of 0.12 Cr..
- For Borrowings, as of Sep 2025, the value is 1.65 Cr.. The value appears to be increasing, which may not be favorable. However, Reserves are negative, which is a major warning sign. It has increased from 1.49 Cr. (Mar 2025) to 1.65 Cr., marking an increase of 0.16 Cr..
- For Other Liabilities, as of Sep 2025, the value is 0.08 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.08 Cr..
- For Total Liabilities, as of Sep 2025, the value is 0.12 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.08 Cr. (Mar 2025) to 0.12 Cr., marking an increase of 0.04 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 0.12 Cr.. The value appears strong and on an upward trend. It has increased from 0.08 Cr. (Mar 2025) to 0.12 Cr., marking an increase of 0.04 Cr..
- For Total Assets, as of Sep 2025, the value is 0.12 Cr.. The value appears strong and on an upward trend. It has increased from 0.08 Cr. (Mar 2025) to 0.12 Cr., marking an increase of 0.04 Cr..
However, the Borrowings (1.65 Cr.) are higher than the Reserves (-7.46 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -5.67 | -8.31 | -8.57 | -8.73 | -10.45 | -4.77 | -6.17 | -2.73 | -1.62 | -2.13 | -1.54 | -1.79 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 53.46 | 57.74 | 53.87 | 56.30 | 102.74 | 135.81 | 79.20 | 91.11 | 34.53 | |||
| Inventory Days | 109.25 | 77.67 | 46.15 | 55.54 | 181.31 | 832.82 | 81.53 | 46.98 | 197.71 | 0.00 | ||
| Days Payable | 45.42 | 43.12 | 41.39 | 49.24 | 63.34 | 436.97 | 41.89 | 28.91 | 342.19 | |||
| Cash Conversion Cycle | 117.30 | 92.30 | 58.62 | 62.60 | 220.71 | 531.66 | 118.84 | 109.18 | -109.95 | |||
| Working Capital Days | 47.76 | 24.71 | -6.46 | -29.53 | -139.69 | -317.99 | -72.00 | -66.89 | -764.53 | |||
| ROCE % | 4.29% | 3.39% | 2.84% | 2.00% | 1.98% | 0.59% | -40.35% | -23.83% | -10.95% | 5.90% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -0.21 | -0.25 | -7.24 | 1.23 | -2.19 |
| Diluted EPS (Rs.) | -0.21 | -0.25 | -7.24 | 1.23 | -2.19 |
| Cash EPS (Rs.) | -0.22 | -0.25 | -7.09 | 1.83 | -0.44 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | -2.55 | -2.93 | -2.68 | 4.53 | 3.30 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | -2.55 | -2.93 | -2.68 | 4.53 | 3.30 |
| Revenue From Operations / Share (Rs.) | 0.00 | 0.00 | 0.00 | 1.26 | 10.82 |
| PBDIT / Share (Rs.) | -0.07 | -0.24 | 0.33 | -0.19 | -0.38 |
| PBIT / Share (Rs.) | -0.07 | -0.24 | 0.18 | -0.78 | -2.14 |
| PBT / Share (Rs.) | -0.35 | -0.24 | -7.24 | 1.15 | -2.19 |
| Net Profit / Share (Rs.) | -0.22 | -0.25 | -7.24 | 1.23 | -2.19 |
| PBDIT Margin (%) | 0.00 | 0.00 | 0.00 | -15.18 | -3.60 |
| PBIT Margin (%) | 0.00 | 0.00 | 0.00 | -62.71 | -19.77 |
| PBT Margin (%) | 0.00 | 0.00 | 0.00 | 91.22 | -20.28 |
| Net Profit Margin (%) | 0.00 | 0.00 | 0.00 | 97.44 | -20.28 |
| Return on Networth / Equity (%) | 0.00 | 0.00 | 0.00 | 27.10 | -66.47 |
| Return on Capital Employeed (%) | -74.83 | 10.03 | -8.69 | -15.66 | -53.59 |
| Return On Assets (%) | -175.09 | -347.38 | -6858.26 | 14.72 | -22.77 |
| Long Term Debt / Equity (X) | -0.99 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Debt / Equity (X) | -0.99 | -0.86 | -0.85 | 0.49 | 1.30 |
| Asset Turnover Ratio (%) | 0.00 | 0.00 | 0.00 | 0.14 | 0.95 |
| Current Ratio (X) | 4.46 | 0.02 | 0.04 | 0.22 | 0.60 |
| Quick Ratio (X) | 4.46 | 0.02 | 0.04 | 0.09 | 0.48 |
| Interest Coverage Ratio (X) | -0.27 | 0.00 | 0.00 | -15.19 | -6.97 |
| Interest Coverage Ratio (Post Tax) (X) | 0.17 | 0.00 | 0.00 | -56.48 | -38.25 |
| Enterprise Value (Cr.) | 9.18 | 18.23 | 4.43 | 5.11 | 5.64 |
| EV / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 6.93 | 0.89 |
| EV / EBITDA (X) | -204.49 | -124.95 | 22.32 | -45.65 | -24.76 |
| MarketCap / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 5.21 | 0.47 |
| Price / BV (X) | -5.20 | -9.80 | -2.02 | 1.45 | 1.55 |
| Price / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 5.21 | 0.47 |
| EarningsYield | -0.01 | -0.01 | -1.34 | 0.18 | -0.43 |
After reviewing the key financial ratios for Adline Chem Lab Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -0.21. This value is below the healthy minimum of 5. It has increased from -0.25 (Mar 24) to -0.21, marking an increase of 0.04.
- For Diluted EPS (Rs.), as of Mar 25, the value is -0.21. This value is below the healthy minimum of 5. It has increased from -0.25 (Mar 24) to -0.21, marking an increase of 0.04.
- For Cash EPS (Rs.), as of Mar 25, the value is -0.22. This value is below the healthy minimum of 3. It has increased from -0.25 (Mar 24) to -0.22, marking an increase of 0.03.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -2.55. It has increased from -2.93 (Mar 24) to -2.55, marking an increase of 0.38.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -2.55. It has increased from -2.93 (Mar 24) to -2.55, marking an increase of 0.38.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.00. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -0.07. This value is below the healthy minimum of 2. It has increased from -0.24 (Mar 24) to -0.07, marking an increase of 0.17.
- For PBIT / Share (Rs.), as of Mar 25, the value is -0.07. This value is below the healthy minimum of 0. It has increased from -0.24 (Mar 24) to -0.07, marking an increase of 0.17.
- For PBT / Share (Rs.), as of Mar 25, the value is -0.35. This value is below the healthy minimum of 0. It has decreased from -0.24 (Mar 24) to -0.35, marking a decrease of 0.11.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -0.22. This value is below the healthy minimum of 2. It has increased from -0.25 (Mar 24) to -0.22, marking an increase of 0.03.
- For PBDIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Net Profit Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Return on Networth / Equity (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 15. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Return on Capital Employeed (%), as of Mar 25, the value is -74.83. This value is below the healthy minimum of 10. It has decreased from 10.03 (Mar 24) to -74.83, marking a decrease of 84.86.
- For Return On Assets (%), as of Mar 25, the value is -175.09. This value is below the healthy minimum of 5. It has increased from -347.38 (Mar 24) to -175.09, marking an increase of 172.29.
- For Long Term Debt / Equity (X), as of Mar 25, the value is -0.99. This value is below the healthy minimum of 0.2. It has decreased from 0.00 (Mar 24) to -0.99, marking a decrease of 0.99.
- For Total Debt / Equity (X), as of Mar 25, the value is -0.99. This value is within the healthy range. It has decreased from -0.86 (Mar 24) to -0.99, marking a decrease of 0.13.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.00. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Current Ratio (X), as of Mar 25, the value is 4.46. This value exceeds the healthy maximum of 3. It has increased from 0.02 (Mar 24) to 4.46, marking an increase of 4.44.
- For Quick Ratio (X), as of Mar 25, the value is 4.46. This value exceeds the healthy maximum of 2. It has increased from 0.02 (Mar 24) to 4.46, marking an increase of 4.44.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -0.27. This value is below the healthy minimum of 3. It has decreased from 0.00 (Mar 24) to -0.27, marking a decrease of 0.27.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.17. This value is below the healthy minimum of 3. It has increased from 0.00 (Mar 24) to 0.17, marking an increase of 0.17.
- For Enterprise Value (Cr.), as of Mar 25, the value is 9.18. It has decreased from 18.23 (Mar 24) to 9.18, marking a decrease of 9.05.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EV / EBITDA (X), as of Mar 25, the value is -204.49. This value is below the healthy minimum of 5. It has decreased from -124.95 (Mar 24) to -204.49, marking a decrease of 79.54.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is -5.20. This value is below the healthy minimum of 1. It has increased from -9.80 (Mar 24) to -5.20, marking an increase of 4.60.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EarningsYield, as of Mar 25, the value is -0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded -0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Adline Chem Lab Ltd:
- Net Profit Margin: 0%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -74.83% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0.17
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 4.46
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 52.1)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: -0.99
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Office No. 904, 9th Floor, Shapath-I Complex, Ahmedabad Gujarat 380054 | info@kamronlabs.com http://www.kamronlabs.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Devarshi D Patel | Independent Director |
| Dr. Mahendra P Shah | Chairman & Ind.Director |
| Mr. Kamlesh J Laskari | Managing Director |
| Ms. Ranak K Laskari | Director |
Adline Chem Lab Ltd. Share Price Update | |
|---|---|
| Share Price | Value |
| Today | ₹19.07 |
| Previous Day | ₹19.07 |
FAQ
What is the intrinsic value of Adline Chem Lab Ltd?
Adline Chem Lab Ltd's intrinsic value (as of 10 December 2025) is 5.05 which is 33.55% lower the current market price of 7.60, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 4.45 Cr. market cap, FY2025-2026 high/low of 22.2/7.60, reserves of ₹-7.46 Cr, and liabilities of 0.12 Cr.
What is the Market Cap of Adline Chem Lab Ltd?
The Market Cap of Adline Chem Lab Ltd is 4.45 Cr..
What is the current Stock Price of Adline Chem Lab Ltd as on 10 December 2025?
The current stock price of Adline Chem Lab Ltd as on 10 December 2025 is 7.60.
What is the High / Low of Adline Chem Lab Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Adline Chem Lab Ltd stocks is 22.2/7.60.
What is the Stock P/E of Adline Chem Lab Ltd?
The Stock P/E of Adline Chem Lab Ltd is .
What is the Book Value of Adline Chem Lab Ltd?
The Book Value of Adline Chem Lab Ltd is 2.75.
What is the Dividend Yield of Adline Chem Lab Ltd?
The Dividend Yield of Adline Chem Lab Ltd is 0.00 %.
What is the ROCE of Adline Chem Lab Ltd?
The ROCE of Adline Chem Lab Ltd is %.
What is the ROE of Adline Chem Lab Ltd?
The ROE of Adline Chem Lab Ltd is %.
What is the Face Value of Adline Chem Lab Ltd?
The Face Value of Adline Chem Lab Ltd is 10.0.